Evidence map›Paper›PMID 39456057›Full record

ArticleJournal of ovarian research2024

Inter-cycle variability of anti-Müllerian hormone: implications for predicting controlled ovarian stimulation cycle outcomes.

Yavuz Emre Şükür, Batuhan Aslan, Necati Berk Kaplan, Musa Doğru, Batuhan Özmen, Murat Sönmezer, Bülent Berker, Cem Somer Atabekoğlu, Ruşen Aytaç

Abstract read
In one paragraph

Article in Journal of ovarian research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yavuz Emre ŞükürDepartment of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkiye, Türkiye. yesukur@gmail.com.
Batuhan AslanDepartment of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkiye, Türkiye.
Necati Berk KaplanDepartment of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkiye, Türkiye.
Musa DoğruDepartment of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkiye, Türkiye.
Batuhan ÖzmenDepartment of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkiye, Türkiye.
Murat SönmezerDepartment of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkiye, Türkiye.
Bülent BerkerDepartment of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkiye, Türkiye.
Cem Somer AtabekoğluDepartment of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkiye, Türkiye.
Ruşen AytaçDepartment of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkiye, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-Müllerian hormone (AMH) is a widely used marker for estimating ovarian reserve, and it may predict response to ovarian stimulation. While AMH is considered a stable, cycle-independent marker, studies have shown it can exhibit significant fluctuations based on factors like age, reproductive stage, and menstrual cycle phase. The fluctuations in AMH levels can make it challenging to predict individual responses accurately, particularly when the AMH is not measured in the COS cycle. The aim of this study was to assess the inter-cycle variability of serum AMH levels in two consecutive menstrual cycles and their correlation with response to controlled ovarian stimulation outcome in the latter.

methodsIn this single-centre retrospective cohort study, data of normal and low responder patients who underwent intracytoplasmic sperm injection following a GnRH antagonist cycle at a university hospital infertility clinic between January 2022 and December 2023 were reviewed. Serum AMH levels were measured in the early follicular phase of two consecutive menstrual cycles with Elecsys-AMH Roche

resultsA total of 79 patients were included in the final analyses. Significant cycle-to-cycle variation in serum AMH levels was observed, with a median variation of 44.3%. Normal responders exhibited a mean change of 0.60 ± 0.46 ng/ml, while poor responders had a mean change of 0.28 ± 0.28 ng/ml. Approximately 20% of patients were reclassified between normal and poor responder categories based on the second AMH measurement. The controlled ovarian stimulation cycle AMH levels showed a stronger correlation with both total oocyte count (r = 0.871, P < 0.001) and MII oocyte count (r = 0.820, P < 0.001) compared to preceding cycle AMH levels.

conclusionAMH levels can exhibit significant variations between consecutive cycles, potentially leading to misclassification of patients. Measuring AMH in the early follicular phase of the COS cycle provides a more accurate prediction of the numbers of total and MII oocytes collected. Consistent and repeated AMH measurements can help clinical decision-making.

Indexed as

Anti-Mullerian HormoneMenstrual CycleOvulation InductionAdultFemaleHumansOvarian ReserveRetrospective StudiesSperm Injections, IntracytoplasmicTreatment OutcomeAnti-Mullerian HormoneAnti-Müllerian hormoneInfertilityInter-cycle variationOvarian reserve test

Identifiers

PMID39456057
PMCPMC11515343

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.